

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/676,526
Filing Date	10/01/2003
First Named Inventor	Patrick H. Roseboom, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	960296.98687

Sheet

1

of

4

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J		Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.	
u		Baker DG, West SA, Nicholson WE, Ekhtor NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geraciotti TD, Jr. (1999) Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 156:585-588.	
u		Bakshi VP, Smith-Roe S, Newman SM, Grigoriadis DE, Kalin NH (2002) Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRF2) receptors in lateral septum or CRF1 receptors in amygdala. J Neurosci 22:2926-2935.	
u		Beglinger C, Degen L (2002) Role of thyrotrophin releasing hormone and corticotrophin releasing factor in stress related alterations of gastrointestinal motor function. Gut 51 Suppl 1:145-149.	
u		Behan DP, De Souza EB, Lowry PJ, Potter E, Sawchenko P, Vale WW (1995) Corticotropin releasing factor (CRF) BP: a novel regulator of CRF and related peptides. Front Neuroendocrinol 16:362-382.	
u		Behan DP, Khongsaly O, Owens JJ, Chung HD, Nemeroff CB, DeSouza EG (1997) Corticotropin-Releasing Factor (CRF), CRF-BP (CRF-BP), and CRF/CRF-BP Complex in Alzheimer's Disease and Control Postmortem Human Brain. Journal of Neurochemistry 68:2053-2060.	
u		Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624-629.	
u		Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougale C, Cohen D (1996) Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry 39:776-783.	
u		Chen R, Lewis KA, Perrin MH, Vale WW (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 90:8967-8971.	
u		Cortright D, Goosens K, Lesh J, Seasholtz A (1997) Isolation and characterization of the rat corticotropin-releasing hormone (CRF) BP gene: Transcriptional regulation by cyclic adenosine monophosphate and CRF. Endocrinology 138:2098-2108.	

Examiner Signature		Date Considered	9/22/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

5539957

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Application Number	10/676,526
		Filing Date	10/01/2003
		First Named Inventor	Patrick H. Roseboom, et al.
		Group Art Unit	--
		Examiner Name	--
		Attorney Docket Number	960296.98687
Sheet	2	of	4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
u		Coste SC, Quintos RF, Stenzel-Poore MP (2002) Corticotropin-releasing hormone-related peptides and receptors. Emergent regulators of cardiovascular adaptations to stress. Trends Cardiovasc Med 12:176-182.	
		Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G, Nemeroff CB (1996) Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 39:703-707.	
		Gasparotto OC, Ignacio ZM, Lin K, Goncalves S (2002) The effect of different psychological profiles and timings of stress exposure on humoral immune response. Physiol Behav 76:321-326.	
		Guillemin R, Rosenberg B (1955) Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures. Endocrinology 57:599-607.	
		Kostich WA, Chen A, Sperle K, Largent BL (1998) Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor [In Process Citation]. Mol Endocrinol 12:1077-1085.	
		Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 98:7570-7575.	
		Linton EA, Behan DP, Saphier PW, Lowry PJ (1990) Corticotropin-Releasing Hormone (CRF)-BP: Reduction in the Adrenocorticotropin-Releasing Activity of Placental but not Hypothalamic CRF. Journal of Endocrinology and Metabolism 70:1574-1580.	
		Lovenberg TW, Liaw CW, Grigoriadis DE, Clevanger W, Chalmers DT, De Souza EB, Oltersdorf T (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain [published erratum appears in Proc Natl Acad Sci U S A 1995 Jun 6;92(12):5759]. Proc Natl Acad Sci U S A 92:836-840.	
		McGaugh JL, Roozendaal B (2002) Role of adrenal stress hormones in forming lasting memories in the brain. Curr Opin Neurobiol 12:205-210.	
		Mitchell AJ (1998) The role of corticotropin releasing factor in depressive illness: a critical review. Neurosci Biobehav Rev 22:635-651.	
k		Nemeroff CB (1989) Clinical Significance of Psychoneuroendocrinology in Psychiatry: Focus on the Thyroid and Adrenal. J Clin Psychiatry 50:13-20.	

Examiner Signature		Date Considered	7/22/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5540706

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/676,526
		Filing Date	10/01/2003
		First Named Inventor	Patrick H. Roseboom, et al.
		Group Art Unit	--
		Examiner Name	--
		Attorney Docket Number	960296.98687
Sheet	3	of	4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
K		Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P, Vale W (1995) Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 92:2969-2973.	
		Potter E, Behan DP, Fischer WH, Linton EA, Lowry PJ, Vale WW (1991) Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-BPs. Nature 349:423-425.	
		Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23-33.	
		Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE (2001) Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 98:2843-2848.	
		Tache Y, Martinez V, Million M, Wang L (2001) Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am J Physiol Gastrointest Liver Physiol 280:G173-177.	
		Takahashi LK (2001) Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci Biobehav Rev 25:627-636.	
		Takahashi LK, Ho SP, Livanov V, Graciani N, Americ SP (2001) Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135-142.	
		Vanitallie TB (2002) Stress: A risk factor for serious illness. Metabolism 51:40-45.	
		Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, et al. (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287-292.	
		Veith RC, Lewis N, Langohr JI, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Bissette G, Nemeroff CB, Raskind MA (1993) Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res 46:1-8.	
K		Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181.	

Examiner Signature	<i>Knut K</i>	Date Considered	2/22/04
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5540706

Please type a plus sign (+) inside this box → +

PTO/SB/088 (08-00)


Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <h2 style="margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="margin: 0;"><i>(use as many sheets as necessary)</i></p>		<p>Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"><tr><td style="width: 50%;">Application Number</td><td>10/676,526</td></tr><tr><td>Filing Date</td><td>10/01/2003</td></tr><tr><td>First Named Inventor</td><td>Patrick H. Roseboom, et al.</td></tr><tr><td>Group Art Unit</td><td>--</td></tr><tr><td>Examiner Name</td><td>--</td></tr><tr><td>Attorney Docket Number</td><td>960296.98687</td></tr></table>		Application Number	10/676,526	Filing Date	10/01/2003	First Named Inventor	Patrick H. Roseboom, et al.	Group Art Unit	--	Examiner Name	--	Attorney Docket Number	960296.98687
Application Number	10/676,526														
Filing Date	10/01/2003														
First Named Inventor	Patrick H. Roseboom, et al.														
Group Art Unit	--														
Examiner Name	--														
Attorney Docket Number	960296.98687														
Sheet	4	of	4												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
R		Behan, Dominic C., et al. (1995) Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature 378:284-287.	
R		Behan, Dominic C., et al. (1992) Cloning and Structure of the Human Corticotrophin Releasing Factor-Binding Protein Gene (CRHBP). Genomics 16:63-68.	

Examiner Signature		Date Considered	7/22/04
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

5540706